about
Changes in Clinical Context for Kaposi's Sarcoma and Non-Hodgkin Lymphoma Among People With HIV Infection in the United States.Role of Natural Killer Cells in HIV-Associated Malignancies.Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targetsA single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17.Role of Autophagy in HIV-1 Matrix Protein p17-Driven Lymphangiogenesis.Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis.Combination antiretroviral therapy and cancer risk.Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report.B-cell responses to HIV infection.HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders.HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.4th European Seminars in Virology on Oncogenic and Oncolytic Viruses, in Bertinoro (Bologna), Italy.HIV-1 matrix protein p17 and its variants promote human triple negative breast cancer cell aggressiveness.Head and Neck Lymphomas in HIV Patients: a Clinical Perspective.Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology.Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.Epstein Barr Virus-Associated Hodgkin Lymphoma.Epstein-Barr virus-associated lymphomasLoss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV PatientsHuman Herpesvirus 8 and Lymphoproliferative DisordersA Rare Cause of Acute Kidney Injury: Primary Renal Lymphoma in a Patient with Human Immunodeficiency Virus
P2860
Q36099911-FA05A9E3-63F9-49FF-92F7-905BAB767A82Q37712593-A7C73B43-7CC5-4699-80F8-0E5D31E964B5Q38599063-29E17A31-5DA7-4667-8393-AADDC5FC42A8Q38659232-FB561A9D-FCD0-4C77-BA02-9733BC77C703Q38673536-08C50B7D-588C-4D47-818A-9530037F5A7DQ38963668-72A95BF5-83DB-4E74-9A92-489549320204Q38983067-278DBEF6-37CC-4EC6-88A4-F8E9EB7C97BAQ38984209-6E162D0C-E661-4E5A-8565-836F585B44F5Q39091833-7B2AD4F3-4B63-4369-AC76-43B688B5A8E5Q39108710-77E4BF25-5981-43EC-BA0A-1FA1C1FD1D0AQ40058240-CBC781D0-6E37-47B1-8B36-B322A54F7264Q40271342-82C88C58-B727-469F-9087-4EBF438A5BB9Q40470227-9FB60DEE-D5D1-4638-830A-4671004F04ABQ41918626-F5887AF9-FD18-43C0-A6AE-975279FE2B57Q41919568-4A918327-5B70-4F9C-A853-6DE4E0E86FD3Q46528091-C96681F2-6819-40DB-866A-FE9302974D49Q47266595-988805AE-6621-401A-9F4F-9962B01D10ADQ55515380-0203401D-A173-4DFB-BB1B-376CC7F69D7BQ56930876-70FF89BE-4C85-4C37-993B-179176B90E03Q58583848-1806C57E-E31A-478A-862D-B2ACCB9076C2Q58701113-B396B21D-D943-4B71-B20E-B0EE77937A76Q58785007-E5C8FE35-465B-4286-B852-1B7E5B9E8510
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A lymphomagenic role for HIV beyond immune suppression?
@ast
A lymphomagenic role for HIV beyond immune suppression?
@en
A lymphomagenic role for HIV beyond immune suppression?
@nl
type
label
A lymphomagenic role for HIV beyond immune suppression?
@ast
A lymphomagenic role for HIV beyond immune suppression?
@en
A lymphomagenic role for HIV beyond immune suppression?
@nl
prefLabel
A lymphomagenic role for HIV beyond immune suppression?
@ast
A lymphomagenic role for HIV beyond immune suppression?
@en
A lymphomagenic role for HIV beyond immune suppression?
@nl
P2860
P50
P1433
P1476
A lymphomagenic role for HIV beyond immune suppression?
@en
P2093
Arnaldo Caruso
P2860
P304
P356
10.1182/BLOOD-2015-11-681411
P407
P577
2016-01-14T00:00:00Z